| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
AMPD2 inhibitor 1 targets adenosine monophosphate deaminase 2 (AMPD2), a key enzyme in purine metabolism that catalyzes the deamination of adenosine monophosphate (AMP) to inosine monophosphate (IMP). By inhibiting AMPD2, the compound modulates cellular energy metabolism and nucleotide synthesis, affecting metabolic homeostasis. AMPD2 plays an important role in regulating AMP levels and downstream signaling pathways that influence reward processing and metabolic sensing in the central nervous system.
|
|---|---|
| ln Vitro |
In vitro, AMPD2 inhibitor 1 selectively inhibits adenosine monophosphate deaminase 2 (AMPD2), blocking the deamination of AMP to IMP. This inhibition modulates cellular energy metabolism and nucleotide synthesis. The compound is used to study the role of AMPD2 in metabolic pathways and its effects on cellular energy status. Its effects on AMP levels and downstream signaling pathways are typically assessed in cell-based assays measuring nucleotide levels and metabolic flux.
|
| ln Vivo |
In vivo studies of AMPD2 inhibitor 1 are focused on evaluating its effects on behavior and metabolism in animal models. Pharmacological inhibition of AMPD2 has been shown to modulate behavioral responses associated with nutrient preference and reward, including sugar, salt, and umami craving. It is widely used in preclinical research focused on addiction-related behaviors, including alcohol, nicotine, tobacco, and other substance dependencies. Further studies are needed to fully characterize its efficacy and safety profile.
|
| Enzyme Assay |
For in vitro enzyme/receptor binding assays, AMPD2 inhibitor 1 can be evaluated using enzymatic activity assays that measure AMPD2-mediated conversion of AMP to IMP. The compound is incubated with recombinant AMPD2 enzyme and AMP substrate at various concentrations. AMPD2 activity is quantified by measuring the production of IMP or the decrease in AMP using HPLC, mass spectrometry, or coupled enzyme assays. IC₅0 values are determined from dose-response curves. Selectivity profiling against other AMPD isoforms may be performed.
|
| Cell Assay |
For in vitro cellular experiments, AMPD2 inhibitor 1 is tested in cell lines to evaluate its effects on purine metabolism and energy homeostasis. Cells are cultured in appropriate media and treated with various concentrations of the compound. Cellular AMP and IMP levels are measured using HPLC or mass spectrometry. The compound's effects on cell viability, proliferation, and metabolic activity are assessed using standard assays. Its effects on downstream signaling pathways, such as AMPK, can be investigated by Western blotting.
|
| Animal Protocol |
For in vivo animal experiments, AMPD2 inhibitor 1 can be administered to rodents via various routes, including oral gavage, intravenous injection, or intraperitoneal injection. The compound is used in models of addiction and reward processing to evaluate its effects on cravings for sugar, salt, and umami, as well as drug, tobacco, nicotine, and alcohol addictions. Behavioral assays, such as conditioned place preference or self-administration, are used to assess the compound's effects on reward-related behaviors.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of AMPD2 inhibitor 1 are not extensively detailed in the provided references. As a small molecule with a molecular weight of 382.45, it may have reasonable oral bioavailability and tissue distribution. The compound is soluble in DMSO and should be stored at -20degC. Detailed parameters such as Cₘₐₓ, Tₘₐₓ, AUC, half-life, and clearance would need to be determined through comprehensive PK studies.
|
| Toxicity/Toxicokinetics |
Toxicological data for AMPD2 inhibitor 1 are limited, as it is primarily a research tool. As an AMPD2 inhibitor, its toxicity would depend on the importance of AMPD2 for normal cellular function and metabolism. Comprehensive toxicology studies including acute and repeated-dose toxicity, genotoxicity, and cardiotoxicity assessments would be needed for further development. Appropriate safety precautions should be taken when handling this compound.
|
| Additional Infomation |
AMPD2 inhibitor 1 is a research compound used to study AMPD2 biology and its role in metabolism and reward processing. No clinical trials or regulatory approvals have been reported for this compound as a therapeutic agent. It is available from various chemical suppliers for research purposes only. The compound is used to study cravings for sugar, salt, and umami, as well as addictions to drugs, tobacco, nicotine, and alcohol.
|
| Molecular Formula |
C25H22N2O2
|
|---|---|
| Molecular Weight |
382.45
|
| Exact Mass |
382.168
|
| CAS # |
2139356-35-5
|
| PubChem CID |
91970654
|
| Appearance |
Off-white to light yellow solid powder
|
| LogP |
2.3
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
29
|
| Complexity |
531
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
C[C@H](C1=CC=CC2=CC=CC=C21)NCC3=CC=C(C=C3)C4=NC=C(C=C4)C(=O)O
|
| InChi Key |
YZNXMOIDDMETFM-QGZVFWFLSA-N
|
| InChi Code |
InChI=1S/C25H22N2O2/c1-17(22-8-4-6-19-5-2-3-7-23(19)22)26-15-18-9-11-20(12-10-18)24-14-13-21(16-27-24)25(28)29/h2-14,16-17,26H,15H2,1H3,(H,28,29)/t17-/m1/s1
|
| Chemical Name |
6-[4-[[[(1R)-1-naphthalen-1-ylethyl]amino]methyl]phenyl]pyridine-3-carboxylic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~33.33 mg/mL (~87.15 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 2.5 mg/mL (6.54 mM) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), suspension solution; with sonication.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (6.54 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 1.25 mg/mL (3.27 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.6147 mL | 13.0736 mL | 26.1472 mL | |
| 5 mM | 0.5229 mL | 2.6147 mL | 5.2294 mL | |
| 10 mM | 0.2615 mL | 1.3074 mL | 2.6147 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
